Summary:
Von Hipple-Lindau syndrome (retinal cerebellar
hemangioblastomatosis)
T1-weighted gadolinium-enhanced MRI of the brain revealed a cystic
mass in the right cerebellar hemisphere with a peripheral enhancing
mural nodule (figure 1). Ultrasound of the kidneys revealed
multiple bilateral renal cysts in ad
Diagnosis
Von Hipple-Lindau syndrome (retinal cerebellar
hemangioblastomatosis)
Findings
T1-weighted gadolinium-enhanced MRI of the brain revealed a cystic
mass in the right cerebellar hemisphere with a peripheral enhancing
mural nodule (figure 1). Ultrasound of the kidneys revealed
multiple bilateral renal cysts in addition to several
solid-appearing lesions (figure 2). To further characterize the
patient's renal abnormalities, a contrast-enhanced CT and an
abdominal MRI were performed. CT of the abdomen showed multiple
exophytic renal cysts in addition to bilateral enhancing lesions
compatible with renal cell carcinomas (figure 3). Coronal
T1-weighted MRI clearly depicts the bilateral upper pole lesions
(figure 4). A heavily T2-weighted HASTEMR not only shows the
obvious solid nature of several renal lesions, but also depicts a
small cyst in the head of the pancreas (figure 5).
Discussion
Von Hipple-Lindau syndrome (VHL) or retinal cerebellar
hemangioblastomatosis is an autosomal dominant neurocutaneous
syndrome that exhibits incomplete penetrance and variable
expressivity. The condition is linked to a defect on the short arm
of chromosome 3 and has an incidence of approximately 1 in 40,000
live births. As with other phakomatoses, VHL may show considerable
genetic heterogeneity and is inherited sporadically in up to 70% of
cases.
1 The disease typically presents in the third or
fourth decade and is characterized by cysts, angiomas, and
neoplasms of the central nervous system (CNS) and abdominal
viscera. The diagnostic criteria include the presence of multiple
CNS hemangioblastomas, one hemangioblastoma plus a visceral
manifestation, or one central or visceral manifestation in a
patient with an affected first-order family member.
2 In
addition to retinal and CNS hemangioblastomas, patients are
predisposed to the development of visceral cysts, benign neoplasms
of the epididymis and membranous labyrinth, as well as multiple
renal cell carcinomas and pheochromocytomas. Rare reports exist
describing multiple hepatic and pulmonary hemangioblastomas
occurring in affected patients.
3
This patient had no known affected relatives and presented with
symptoms initially attributed to sinusitis. His complaint of
decreased visual acuity secondary to a retinal angioma is typical
of patients presenting before age 40. Retinal lesions are found in
50% to 60% of patients and are multiple in one-third.4
Angiomas are typically diagnosed by fundoscopic examination and are
occult on imaging studies such as MRI unless hemorrhage and
subretinal exudate is present.The patient's subacute history of
vertigo can be attributed to the large posterior fossa
hemangioblastoma. Cerebellar hemangioblastomas occur in up to
two-thirds of patients with VHL and less commonlyoccur in the
brainstem and spinal cord. The appearance of a cystic mass with an
enhancing vascular muralnodule is typical. Lesions may be
completely solid, however, and are multiple in 40% of patients. The
main diagnostic consideration of such a posterior fossa lesion is a
pilocytic astrocytoma; however, the patient's age, infratentorial
location, and additional visceral findings strongly suggest an
alternate diagnosis. This lesion was excised and confirmed to be a
cerebellar hemangioblastoma. Subsequent genetic testing confirmed
the diagnosis of VHL. Renal cell carcinomas occur in up to 50% of
patients with VHL and represent the leading cause of mortality.
This patient exhibited extensive rena linvolvement with multiple
bilateral cysts and renal cell carcinomas, responsible for the
elevated creatinine and hemoglobin on initial laboratory analysis.
Compared with sporadic renal cellcarcinomas, tumors developing in
patients with VHL tend to occur on average 25 years earlier, are
more often multiple and bilateral, contain cystic organization and
low grade histology, have a better 10-year survival rate, and
rarely metastasize before reaching a size of 7 cm.5
These facts weigh heavily in the optimal surgical management of
patients with multiple bilateral neoplasms, as in this case. At
present, lesions <5 cm with low cytological grade are managed
conservatively in order to obviate radical nephrectomy. In family
members of affected individuals, screening computed tomography may
allow very small lesions to be detected and allow for partial or
limited nephrectomy. Pheochromocytomas are the second most common
visceral malignancy in affected patients,occurring in up to 15%. It
is the prevalence of these neoplasms that link VHL genetically and
phenotypically to other phakomatoses (such as neurofibromatosis
type I and tuberous sclerosis, as well as multiple endocrine
neoplasia type II and isolated familial
pheochromotosis).6 In summary, the considerable
phenotypic heterogeneity of von Hipple-Lindau syndrome, as well as
the preponderance of sporadic occurrence, should be kept in mind
when evaluating patients presenting with focal neurologic signs in
addition to visceral manifestations. The correct diagnosis not only
holds profound implications in the treatment of affected patients,
but allows genetic testing and screening of potentially affected
family members. The proclivity of patients with VHL to present in
late adolescence and early adulthood results in the need for
genetic counseling to address the mode and probability of autosomal
dominant transmission. Ongoing research continues to define the
genetic mutations responsible for VHL and other phakomatoses, with
the hope of some day providing gene-guided therapy as treatment for
the neurocutaneous syndromes.
- Richard S, Beroud C, Joly D, Chretien Y: Von Hipple-Lindau
disease and renal cancer: 10 years of genetic progress. Prog
Urol 8(3):330-339 ,1998.
- Filling-Katz MR, Choyke PL, Patronas NJ: Radiologic screening
for von Hipple-Lindau disease: The role of Gd-DTPA enhanced MR
imaging of the CNS. J Comp Asst Tomogr 13:743-755,
1989.
- McGrath FP, Gibney RG, Morris DC, Owen DA: Multiple hepatic and
pulmonary hemangioblastomas-A new manifestation of von
Hipple-Lindau disease. Clin Radiol 45(1):37-39 1992.
- Braffman BH, Bilaniuk LT, Zimmerman RA: MR of central nervous
system neoplasia of the phakomatoses. Sem Roentgenol
25:198-217,1990.
- Neumann HP, Bender BU, Berger DP, et al: Prevalence,
morphology, and biology of renal cell carcinoma in von
Hipple-Lindau disease compared to sporadic renal cell carcinoma.
J Urol 160:1248-1254, 1998.
- Ritter MM, Frilling A, Crossey PA, et al: Isolated familial
pheochromocytoma as a variant of von Hippel-Lindau disease. J
Clin Endo Metab 81:1035-1037, 1996.